James E. Krause
James E. Krause has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Robbin M. Brodbeck
Department of Molecular Biology and Biochemistry, Neurogen Corporation, Branford, Connecticut, USA
3 shared publicationsAlan J. Hutchison
Departments of Molecular Biology and Biochemistry ( Neurogen Corporation Branford Connecticut
2 shared publications- Andrew D. Hershey
Division of Neurology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
2 shared publications Bertrand L. Chenard
ARMGO Pharma Inc., New York, New York, USA
2 shared publicationsDaniel N Cortright
2 shared publicationsGeorge D. Maynard
Departments of Molecular Biology and Biochemistry ( Neurogen Corporation Branford Connecticut
2 shared publications
Latest Publications
- Open Access
- 1 December 2008
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 327 (3) , 898-909
Identification and Characterization of NDT 9513727 [N,N-bis(1,3-Benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1 H-imidazole-5-methanamine], a Novel, Orally Bioavailable C5a Receptor Inverse Agonist
The complement system represents an innate immune mechanism of host defense that has three effector arms, the C3a receptor, the C5a receptor (C5aR), and the membrane attack complex. Because of its inflammatory and immune-enhancing properties, the biological activity of C5a and its classical receptor have been widely studied. Because specific antagonism of the C5aR could have therapeutic benefit without affecting the protective immune response, the C5aR continues to be a promising target for pharmaceutical research. The lack of specific, potent and orally bioavailable small-molecule antagonists has limited the clinical investigation of the C5aR. We report the discovery of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a small-molecule, orally bioavailable, selective, and potent inverse agonist of the human C5aR. NDT 9513727 was discovered based on the integrated use of in vitro affinity and functional assays in conjunction with medicinal chemistry. NDT 9513727 inhibited C5a-stimulated responses, including guanosine 5′-3-O-(thio)triphosphate binding, Ca2+ mobilization, oxidative burst, degranulation, cell surface CD11b expression and chemotaxis in various cell types with IC50s from 1.1 to 9.2 nM, respectively. In C5a competition radioligand binding experiments, NDT 9513727 exhibited an IC50 of 11.6 nM. NDT 9513727 effectively inhibited C5a-induced neutropenia in gerbil and cynomolgus macaque in vivo. The findings suggest that NDT 9513727 may be a promising new entity for the treatment of human inflammatory diseases.
- 1 December 2008
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 327 (3) , 898-909
Open AccessIdentification and Characterization of NDT 9513727 [N,N-bis(1,3-Benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1 H-imidazole-5-methanamine], a Novel, Orally Bioavailable C5a Receptor Inverse Agonist
The complement system represents an innate immune mechanism of host defense that has three effector arms, the C3a receptor, the C5a receptor (C5aR), and the membrane attack complex. Because of its inflammatory and immune-enhancing properties, the biological activity of C5a and its classical receptor have been widely studied. Because specific antagonism of the C5aR could have therapeutic benefit without affecting the protective immune response, the C5aR continues to be a promising target for pharmaceutical research. The lack of specific, potent and orally bioavailable small-molecule antagonists has limited the clinical investigation of the C5aR. We report the discovery of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a small-molecule, orally bioavailable, selective, and potent inverse agonist of the human C5aR. NDT 9513727 was discovered based on the integrated use of in vitro affinity and functional assays in conjunction with medicinal chemistry. NDT 9513727 inhibited C5a-stimulated responses, including guanosine 5′-3-O-(thio)triphosphate binding, Ca2+ mobilization, oxidative burst, degranulation, cell surface CD11b expression and chemotaxis in various cell types with IC50s from 1.1 to 9.2 nM, respectively. In C5a competition radioligand binding experiments, NDT 9513727 exhibited an IC50 of 11.6 nM. NDT 9513727 effectively inhibited C5a-induced neutropenia in gerbil and cynomolgus macaque in vivo. The findings suggest that NDT 9513727 may be a promising new entity for the treatment of human inflammatory diseases.
- 21 November 2008
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1144 (1) , 243-250
Opportunities and Challenges in the Discovery of New Central Nervous System Drugs
There have been relatively few new mechanism-based approvals for nervous system relevant drugs over the past 5 years, despite the increasing budgets of pharmaceutical and biotechnology companies. The genomic revolution has provided scientists with many molecular targets for drug discovery and research advances in chemistry, drug metabolism, pharmacology, and toxicology have provided much insight into understanding the pitfalls of the drug discovery and development process. Herein is provided a perspective on both the opportunities and challenges in the discovery and development of novel medicines for the treatment of human CNS disorders.
- 21 November 2008
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1144 (1) , 243-250
Opportunities and Challenges in the Discovery of New Central Nervous System Drugs
There have been relatively few new mechanism-based approvals for nervous system relevant drugs over the past 5 years, despite the increasing budgets of pharmaceutical and biotechnology companies. The genomic revolution has provided scientists with many molecular targets for drug discovery and research advances in chemistry, drug metabolism, pharmacology, and toxicology have provided much insight into understanding the pitfalls of the drug discovery and development process. Herein is provided a perspective on both the opportunities and challenges in the discovery and development of novel medicines for the treatment of human CNS disorders.
- 1 June 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (11) , 3376-3381
Aminopyrazine CB1 receptor inverse agonists
- 1 June 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (11) , 3376-3381
Aminopyrazine CB1 receptor inverse agonists
- 1 September 2007
- Published by Springer Nature in Nature Methods
- Vol. 4 (9) , 692-693
Hunting for ion channel modulators with herpes simplex virus
- 1 September 2007
- Published by Springer Nature in Nature Methods
- Vol. 4 (9) , 692-693
Hunting for ion channel modulators with herpes simplex virus
- 1 August 2007
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1772 (8) , 978-988
TRP channels and pain
- 1 August 2007
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1772 (8) , 978-988
TRP channels and pain
- 1 January 2005
- Vol. 6 (1) , 48-57
Transient receptor potential ion channels as targets for the discovery of pain therapeutics.
A subset of transient receptor potential (TRP) channels exhibits activity that is highly sensitive to temperature changes and is expressed in sensory tissues, such as nociceptors and skin. Some of these thermosensitive TRP channels, such as TRPV1, TRPV4 and TRPA1, are activated or sensitized by molecules generated by inflammation and/or cell damage. TRPV1, also known as the capsaicin receptor, is particularly important in mediating hyperalgesic responses in inflammatory pain states, as demonstrated by research in knockout animals and with small-molecule antagonists. It is anticipated that TRPV1 antagonists, and perhaps antagonists at other thermosensitive TRP channels, will provide new therapeutic options with which to treat clinical pain.
- 1 January 2005
- Vol. 6 (1) , 48-57
Transient receptor potential ion channels as targets for the discovery of pain therapeutics.
A subset of transient receptor potential (TRP) channels exhibits activity that is highly sensitive to temperature changes and is expressed in sensory tissues, such as nociceptors and skin. Some of these thermosensitive TRP channels, such as TRPV1, TRPV4 and TRPA1, are activated or sensitized by molecules generated by inflammation and/or cell damage. TRPV1, also known as the capsaicin receptor, is particularly important in mediating hyperalgesic responses in inflammatory pain states, as demonstrated by research in knockout animals and with small-molecule antagonists. It is anticipated that TRPV1 antagonists, and perhaps antagonists at other thermosensitive TRP channels, will provide new therapeutic options with which to treat clinical pain.
- 15 July 2003
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 42 (31) , 9406-9415
C5L2, a Nonsignaling C5A Binding Protein
C5a anaphylatoxin, a potent inflammatory mediator, is known to act through a specific G protein coupled receptor. However, some of the complex effects of C5a in vivo may not be explained solely by the deletion of the known receptor. Here, we show that an orphan receptor, identified as C5L2, is a high affinity C5a binding protein. Unlike the previously described C5aR, C5L2 is obligately uncoupled from heterotrimeric G proteins, in part by virtue of an amino acid alteration in the so-called DRY sequence at the end of the third transmembrane segement. Both human and murine C5L2 bear a leucine for arginine replacement at this site. C5L2, when transfected into several cell types, is weakly phosphorylated in transfected cells following binding of C5a but does not induce significant activation of MAP kinases, mediate calcium flux, or stimulate chemotaxis. Bone marrow cells from wild type respond robustly to C5a with induction and suppression of a number of inflammation related genes. In contrast, C5a receptor deficient mice, which bear C5L2 alone, do not respond to C5a with changes in gene transcription by microarray analyses. Biophysical properties of the C5L2, including slow ligand on and off rates, absence of internalization, and relatively high affinity for the C5a des Arg metabolite, suggest that this receptor may serve to modulate C5a biological functions in vivo. Finally, in contrast to previous reports, we find absolutely no interaction of C5L2 with other anaphylatoxins C3a and C4a.
- 15 July 2003
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 42 (31) , 9406-9415
C5L2, a Nonsignaling C5A Binding Protein
C5a anaphylatoxin, a potent inflammatory mediator, is known to act through a specific G protein coupled receptor. However, some of the complex effects of C5a in vivo may not be explained solely by the deletion of the known receptor. Here, we show that an orphan receptor, identified as C5L2, is a high affinity C5a binding protein. Unlike the previously described C5aR, C5L2 is obligately uncoupled from heterotrimeric G proteins, in part by virtue of an amino acid alteration in the so-called DRY sequence at the end of the third transmembrane segement. Both human and murine C5L2 bear a leucine for arginine replacement at this site. C5L2, when transfected into several cell types, is weakly phosphorylated in transfected cells following binding of C5a but does not induce significant activation of MAP kinases, mediate calcium flux, or stimulate chemotaxis. Bone marrow cells from wild type respond robustly to C5a with induction and suppression of a number of inflammation related genes. In contrast, C5a receptor deficient mice, which bear C5L2 alone, do not respond to C5a with changes in gene transcription by microarray analyses. Biophysical properties of the C5L2, including slow ligand on and off rates, absence of internalization, and relatively high affinity for the C5a des Arg metabolite, suggest that this receptor may serve to modulate C5a biological functions in vivo. Finally, in contrast to previous reports, we find absolutely no interaction of C5L2 with other anaphylatoxins C3a and C4a.
- 1 January 2001
- Published by Elsevier in Brain Research
- Vol. 889 (1-2) , 23-37
Immunohistochemical localization of the neuropeptide Y Y1 receptor in rat central nervous system
- 1 January 2001
- Published by Elsevier in Brain Research
- Vol. 889 (1-2) , 23-37
Immunohistochemical localization of the neuropeptide Y Y1 receptor in rat central nervous system
- 10 April 1997
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 336 (15) , 1094-1096
Pulmonary Inflammation — A Balancing Act
Even in antiquity it was known that inflammation has both beneficial and adverse effects, but only recently have we begun to elucidate how the body maintains a balance between host defenses and tissue injury. This balance is especially important in the lung, where despite protective mechanical and physical forces, noxious agents constantly assault lower respiratory epithelial surfaces.More than 25 years ago, the importance of neurogenic control of pulmonary inflammation was suggested by a study of a tachykinin neuropeptide called substance P.1 Ablation of substance P–producing sensory neurons by capsaicin, the irritant agent in hot pepper, markedly inhibited the noxious . . .
- 10 April 1997
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 336 (15) , 1094-1096
Pulmonary Inflammation — A Balancing Act
Even in antiquity it was known that inflammation has both beneficial and adverse effects, but only recently have we begun to elucidate how the body maintains a balance between host defenses and tissue injury. This balance is especially important in the lung, where despite protective mechanical and physical forces, noxious agents constantly assault lower respiratory epithelial surfaces.More than 25 years ago, the importance of neurogenic control of pulmonary inflammation was suggested by a study of a tachykinin neuropeptide called substance P.1 Ablation of substance P–producing sensory neurons by capsaicin, the irritant agent in hot pepper, markedly inhibited the noxious . . .
- 15 February 1991
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 88 (4) , 1222-1226
Sexually dimorphic distribution of substance P in specific anterior pituitary cell populations.
Substance P (SP) immunoreactivity is detectable in the rat pituitary by RIA; however, immunolocalization has been difficult. We used a sensitive immunogold silver-enhancement staining technique to cytochemically locate SP in the gland. SP-immunoreactive (SP-ir) cells were seen in anterior pituitary (AP), and occasional SP-ir fibers and terminals were seen in both AP and posterior pituitary. Colocalization studies showed the vast majority of SP-ir cells in the male AP to be also immunoreactive for growth hormone (GH). These GH/SP-ir cells represent approximately 23% of the somatotroph population in the male. SP-ir cells did not colocalize with lactotrophs, gonadotrophs, or corticotrophs; however, rare thyroid-stimulating hormone/SP-ir cells were found in the male AP. Comparisons of pituitaries from males and females revealed that females have 70% fewer SP-ir cells and that only approximately 6% of the somatotrophs in the female express SP. This sexual dimorphism is diminished in 6-day ovariectomized rats because this treatment increases the GH/SP-ir cell population 3-fold. This result suggests that the previously reported estrogen-induced decrease in SP gene and peptide expression in the pituitary occurs, at least in part, in a subpopulation of somatotrophs. To test this hypothesis, distribution of SP-ir cells was examined in pituitaries from estrogen- and oil-treated ovariectomized rats. Estrogen reduced the percentage of somatotrophs with SP immunoreactivity by 70% compared with ovariectomized oil-treated controls, indicating that estrogen most likely regulates SP levels in the pituitary by acting on a subpopulation of somatotrophs to suppress SP expression. Estrogen does not appear to alter SP immunoreactivity that is detected in the additional population of SP cells that colocalize with thyroid-stimulating hormone. These SP-expressing thyrotrophs were seen 6-fold more frequently in the female than in the male pituitary, regardless of steroid status. These studies reveal that males have more total SP-ir cells in the AP than do females and that there is a sexually dimorphic pattern of SP distribution in the gland. Males have a higher percentage of SP-ir GH cells, whereas females have more SP-ir thyrotrophs than do males. Identification of independently regulated SP-ir somatotroph and thyrotroph populations provides a basis for investigating the roles of SP in autocrine or paracrine regulation of pituitary hormone secretion.
- 15 February 1991
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 88 (4) , 1222-1226
Sexually dimorphic distribution of substance P in specific anterior pituitary cell populations.
Substance P (SP) immunoreactivity is detectable in the rat pituitary by RIA; however, immunolocalization has been difficult. We used a sensitive immunogold silver-enhancement staining technique to cytochemically locate SP in the gland. SP-immunoreactive (SP-ir) cells were seen in anterior pituitary (AP), and occasional SP-ir fibers and terminals were seen in both AP and posterior pituitary. Colocalization studies showed the vast majority of SP-ir cells in the male AP to be also immunoreactive for growth hormone (GH). These GH/SP-ir cells represent approximately 23% of the somatotroph population in the male. SP-ir cells did not colocalize with lactotrophs, gonadotrophs, or corticotrophs; however, rare thyroid-stimulating hormone/SP-ir cells were found in the male AP. Comparisons of pituitaries from males and females revealed that females have 70% fewer SP-ir cells and that only approximately 6% of the somatotrophs in the female express SP. This sexual dimorphism is diminished in 6-day ovariectomized rats because this treatment increases the GH/SP-ir cell population 3-fold. This result suggests that the previously reported estrogen-induced decrease in SP gene and peptide expression in the pituitary occurs, at least in part, in a subpopulation of somatotrophs. To test this hypothesis, distribution of SP-ir cells was examined in pituitaries from estrogen- and oil-treated ovariectomized rats. Estrogen reduced the percentage of somatotrophs with SP immunoreactivity by 70% compared with ovariectomized oil-treated controls, indicating that estrogen most likely regulates SP levels in the pituitary by acting on a subpopulation of somatotrophs to suppress SP expression. Estrogen does not appear to alter SP immunoreactivity that is detected in the additional population of SP cells that colocalize with thyroid-stimulating hormone. These SP-expressing thyrotrophs were seen 6-fold more frequently in the female than in the male pituitary, regardless of steroid status. These studies reveal that males have more total SP-ir cells in the AP than do females and that there is a sexually dimorphic pattern of SP distribution in the gland. Males have a higher percentage of SP-ir GH cells, whereas females have more SP-ir thyrotrophs than do males. Identification of independently regulated SP-ir somatotroph and thyrotroph populations provides a basis for investigating the roles of SP in autocrine or paracrine regulation of pituitary hormone secretion.